Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model

Chemo- and radio-therapy suffer from certain well-recognized drawbacks for lymphoma therapy. Passive immunotherapy with monoclonal antibody has improved outcome for patients with CD20(+) B cell lymphoma, but not for T cell lymphoma. Therefore, novel treatment approaches are clearly required for T ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Dong, Li, Wang, Wang, Wanmin, Cai, Yongguang, Wang, Yuhuan, Luo, Xiaoling, Wei, Chih-Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665034/
https://www.ncbi.nlm.nih.gov/pubmed/29158790
http://dx.doi.org/10.7150/jca.20015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665034/
https://www.ncbi.nlm.nih.gov/pubmed/29158790
http://dx.doi.org/10.7150/jca.20015

Ejemplares similares